ArticleJournal of chemical information and modeling2025
Auxiliary Discrminator Sequence Generative Adversarial Networks for Few Sample Molecule Generation.
Article in Journal of chemical information and modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fine-Tuning DeepSeek-OCR‑2 for Molecular Structure Recognition.ACS omega · 2026Article
- From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery and the Hurdles to Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
In this work, we introduce auxiliary discriminator sequence generative adversarial networks (ADSeqGAN), a novel approach for molecular generation in small-sample data sets. Traditional generative models often struggle with limited training data, particularly in drug discovery, where molecular data sets for specific therapeutic targets, such as nucleic acid binders and central nervous system (CNS) drugs, are scarce. ADSeqGAN addresses this challenge by integrating an auxiliary random forest classifier as an additional discriminator into the GAN framework, significantly improving molecular generation quality and class specificity. Our method incorporates a pretrained generator and Wasserstein distance to enhance training stability and diversity. We evaluated ADSeqGAN across three representative cases. First, on nucleic acid- and protein-targeting molecules, ADSeqGAN shows superior capability in generating nucleic acid binders compared with baseline models. Second, through oversampling, it markedly improves CNS drug generation, achieving higher yields than traditional de novo models. Third, in cannabinoid receptor type 1 (CB1) ligand design, ADSeqGAN generates novel druglike molecules with 32.8% predicted actives surpassing hit rates of CB1-focused and general-purpose libraries when assessed by a target-specific LRIP-SF scoring function. Overall, ADSeqGAN offers a versatile framework for molecular design in data-scarce scenarios with demonstrated applications in nucleic acid binders, CNS drugs, and CB1 ligands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.